Trinity BiotechTRIB -0.06%20 FCF Margin % is -14.23% as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 20/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 73.99% on this metric.
The historical rank and industry rank for Trinity Biotech's FCF Margin % or its related term are showing as below:
TRIB'
s FCF Margin % Range Over the Past 10 Years
Min: -27.75 Med: -10.75 Max: 13.29
Current: -27.75
During the past 13 years, the highest FCF Margin % of Trinity Biotech was 13.29%. The lowest was -27.75%. And the median was -10.75%.
TRIB's FCF Margin % is ranked worse than 73.99% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs TRIB: -27.75
Trinity Biotech FCF Margin % Related Terms
Trinity Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Trinity Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a FCF Margin % of -14.23% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #603 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 74%.
Is Trinity Biotech's FCF Margin % too high?
Trinity Biotech's current FCF Margin % is -14.23%. Based on the distribution chart, Trinity Biotech ranks #603 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Trinity Biotech has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's FCF Margin % compare to PMI and NXL?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #603 out of 815 companies for FCF Margin %. This places Trinity Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current FCF Margin % is -14.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.35 — trading 52.1% below its estimated fair value. The current FCF Margin % is -14.23%. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current FCF Margin % is -14.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.35 is trading 52.1% below its estimated GF Value™ of $0.73.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
FCF Margin %: -14.23%
GF Value™: $0.73 vs. price of $0.35 (52.1% below fair value)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score
Get the complete analysis for TRIB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
